Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Hari Menon, Dawei Chen, Rishab Ramapriyan, Vivek Verma, Hampartsoum B Barsoumian, Taylor R Cushman, Ahmed I Younes, Maria A Cortez, Jeremy J Erasmus, Patricia de Groot, Brett W Carter, David S Hong, Isabella C Glitza, Renata Ferrarotto, Mehmet Altan, Adi Diab, Stephen G Chun, John V Heymach, Chad Tang, Quynh N Nguyen, James W Welsh, Hari Menon, Dawei Chen, Rishab Ramapriyan, Vivek Verma, Hampartsoum B Barsoumian, Taylor R Cushman, Ahmed I Younes, Maria A Cortez, Jeremy J Erasmus, Patricia de Groot, Brett W Carter, David S Hong, Isabella C Glitza, Renata Ferrarotto, Mehmet Altan, Adi Diab, Stephen G Chun, John V Heymach, Chad Tang, Quynh N Nguyen, James W Welsh
Abstract
Background: Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor's response to immunotherapy, when combined with high-dose radiation to another tumor. The aim of this study was to evaluate tumor responses to this combination in a clinical setting.
Methods: A post-hoc analysis of 3 ongoing immunoradiation trials was performed. Twenty-six (of 155) patients received low-dose radiation (1-20 Gy total), either as scatter from high-dose radiation or from intentional treatment of a second isocenter with low-dose radiation, were evaluated for response. The low-dose lesions were compared to lesions that received no radiation (< 1 Gy total). Response rates, both defined as complete and partial responses as defined by RECIST criteria were used to compare lesion types.
Results: The 26 patients had a total of 83 lesions for comparison (38 receiving low-dose, 45 receiving no-dose). The average dose given to low-dose lesions was 7.3 Gy (1.1-19.4 Gy), and the average time to response was 56 days. Twenty-two out of 38 (58%) low-dose lesions met the PR/CR criteria for RECIST compared with 8 out of 45 (18%) no-dose lesions (P = 0.0001). The median change for longest diameter size for low-dose lesions was - 38.5% compared to 8% in no-dose lesions (P < 0.0001). Among the low-dose lesions that had at least one no-dose lesion within the same patient as a control (33 and 45 lesions respectively), 12 low-dose lesions (36%) responded without a corresponding response in their no-dose lesions; Conversely, two (4%) of the no-dose lesions responded without a corresponding response in their low-dose lesion (P = 0.0004).
Conclusions: Low-dose radiation may increase systemic response rates of metastatic disease treated with high-dose radiation and immunotherapy.
Keywords: Abscopal effect; Immunotherapy; Low-dose radiotherapy; Metastatic cancer; Stereotactic ablative radiation therapy.
Conflict of interest statement
ICG, MA, JVH and DSH have received research grants from Bristol-Myers Squibb. JWW, ICG, JVH, and DSH also receive research funding from Merck. MA receives research funding from Novartis and Lilly. DSH and JWW are founders and have ownership interest in OncoResponse and MolecularMatch. All other authors declare no conflicts of interest. JWW reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck , Nanobiotix, Mavu Pharma and Checkmate Pharmaceuticals. JWW serves on the scientific advisory board for RefleXion Medical, MolecularMatch, OncoResponse, CheckMate, Mavu Pharmaceuticals, Alpine Immune Sciences. He is co-founder of Healios Oncology, MolecularMatch, and OncoResponse and serves as an advisor to Astra Zeneca, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. JWW has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM.
Figures
References
- Mole RH. Whole body irradiation—radiobiology or medicine? Br J Radiol. 1953;26(305):234–241. doi: 10.1259/0007-1285-26-305-234.
- Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40(1):25–37. doi: 10.1016/j.currproblcancer.2015.10.001.
- Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602. doi: 10.1016/j.ccr.2013.09.014.
- Barsoumian H, Cushman TR, Caetano MDS, Cadena A, Younes A, Tang C, et al. Low dose radiation improves anti-tumor responses in a phase 2 prospective trial of concurrent or sequential stereotactic radiation and Ipilimumab in patients with metastatic lesions. Int J Radiat Oncol Biol Phys. 2018;102(3):S26. doi: 10.1016/j.ijrobp.2018.06.149.
- Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth and Metastasis. 2018;11:1179064418761639. doi: 10.1177/1179064418761639.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI. 2000;92(3):205–216. doi: 10.1093/jnci/92.3.205.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
- Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley K. E, et al. radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271. doi: 10.1084/jem.20052494.
- Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803. doi: 10.1016/S1470-2045(15)00054-6.
- Cushman TR, Caetano MS, Welsh JW, Verma V. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy. 2018;10(10):851–800. doi: 10.2217/imt-2018-0019.
- Verma V, Cushman TR, Tang C, Welsh JW. Toxicity of radiation and immunotherapy combinations. Adv Radiat Oncol. 2018;3(4):506–511. doi: 10.1016/j.adro.2018.08.003.
- Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I/II trials. Int J Radiat Oncol Biol Phys. 2018;101(5):1141–1148. doi: 10.1016/j.ijrobp.2018.04.054.
- Pilepich MV, Vietti TJ, Nesbit ME, Tefft M, Kissane J, Omer Burgert E, et al. Radiotherapy and combination chemotherapy in advanced Ewing's sarcoma–intergroup study. Cancer. 1981;47(8):1930–1936. doi: 10.1002/1097-0142(19810415)47:8<1930::AID-CNCR2820470803>;2-3.
- Dunst J, Paulussen M, Juergens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlenther Onkol. 1993;169(10):621–623.
- Spunt SL, McCarville MB, Kun LE, Poquette CA, Cain AM, Brandao L, et al. Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis. J Pediatr Hematol Oncol. 2001;23(2):93–98. doi: 10.1097/00043426-200102000-00005.
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi: 10.1056/NEJMoa1504030.
- Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391.
- Oh A, Tran DM, McDowell LC, Keyvani D, Barcelon JA, Merino O, et al. Cost-effectiveness of Nivolumab-Ipilimumab combination therapy compared with monotherapy for first-line treatment of metastatic melanoma in the United States. J Manag Care Spec Pharm. 2017;23(6):653–664.
Source: PubMed